Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update
Verona Pharma plc - American Depositary Shares (VRNA)
US:NASDAQ Investor Relations:
nasdaq.com/symbol/vrna/real-time
Company Research
Source: GlobeNewswire
Post-period end, reported positive top-line Phase 2b results with nebulized ensifentrine and senior management changes Conference Call Today at 9:00 am EST / 2:00 pm GMT LONDON, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces its unaudited results for the full year ended December 31, 2019, and provides a corporate update. “We believe that 2020 will be a transformative year for Verona Pharma. Both Mark Hahn and I are very pleased to have joined Verona, where we can leverage our experience in leading pharmaceutical companies through late-stage clinical trials and into commercialization of innovative therapeutics like ensifentrine,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer. “We are looking forward to our planned End-of-Phase 2 meeting with the U.S. FDA in the second q
Show less
Read more
Impact Snapshot
Event Time:
VRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRNA alerts
High impacting Verona Pharma plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VRNA
News
- Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsightPR Newswire
- Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsightPR Newswire
- Verona Pharma Announces December 2024 Investor Conference Participation [Yahoo! Finance]Yahoo! Finance
- Verona Pharma Announces December 2024 Investor Conference ParticipationGlobeNewswire
- Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman [Yahoo! Finance]Yahoo! Finance
VRNA
Sec Filings
- 12/6/24 - Form 4
- 12/6/24 - Form 4
- 12/2/24 - Form 4
- VRNA's page on the SEC website